Please Note: This session was developed by Pear Therapeutics and is not accredited for continuing pharmacy education credit.
After witnessing and recognizing how innovation is reshaping our current health care system, Pear Therapeutics — the industry leader of prescription digital therapeutics (PDT) — has partnered with Avalere — a leading health care consulting firm — to develop and publish the Pear Therapeutics Prescription Digital Therapeutics Digest (Pear PDT Digest). The Digest is a series of publications unpacking how PDTs are poised to disrupt care delivery and benefit major stakeholders throughout the health care system.
The session will include a final publication which incorporates findings from a survey of major U.S. payers, employers, and other key stakeholders, including their views around PDT awareness, coverage frameworks, and other key trends impacting the PDT marketplace.
- Demonstrate PDTs as a new innovation modality for their ability to solve major gaps in care delivery and enhance disease treatment outcomes.
- Identify barriers and generate discussion around expanding pathways to coverage of PDTs that show strong clinical and real-world benefit.
- Showcase results from a survey conducted by Avalere and Pear to highlight current barriers to and opportunities for expanding patient access to PDTs.
Patrick P. Gleason, PharmD, BCPS, FCCP, FAMCP
Assistant Vice President, Health Outcomes
Yuri Maricich, MD
Chief Medical Officer
Robert O'Brien, RPh
John Fox, MD, MHA
Foxworthy Healthcare Consulting, LLC
System Technical Requirements/Viewing Requirements:
System Requirements Courses and learning activities are delivered via your Web browser and Acrobat PDF. For all activities, you should have a basic comfort level using a computer and navigating websites. View the minimum technical and system requirements for continuing education online learning activities.